ExonHit awarded QTDP grants for AclarusDx and EHT 107 programs

“These awards also further highlight the ability of our Genome-Wide SpliceArray™ discovery platform to generate both innovative diagnostic and therapeutic products. These grants will contribute to support the ongoing development of two programs targeting areas of high medical need.”

ExonHit Therapeutics (Paris:ALEHT)(Alternext: ALEHT) today announced that the Company was awarded two grants to support two of its Research & Development projects under the Qualifying Therapeutic Discovery Project Program: AclarusDx™ in Alzheimer's disease and the EHT 107 program in oncology.

"We are excited to benefit from these grants as they are a recognition of the potential medical benefit of AclarusDx™ and the EHT 107 program," said Matthew Pando, PhD, Executive Vice President, Therapeutics of ExonHit Therapeutics. "These awards also further highlight the ability of our Genome-Wide SpliceArray™ discovery platform to generate both innovative diagnostic and therapeutic products. These grants will contribute to support the ongoing development of two programs targeting areas of high medical need."

These two grants totaling USD 0.3 million were awarded to ExonHit by the U.S. Secretary of Health and Human Services to support its Alzheimer's disease and oncology research and development projects. Among the determining criteria used by the Secretary in allocating funds were those projects that show potential to result in new therapies to treat areas of unmet medical need.

SOURCE ExonHit Therapeutics